Besides, in IDH1/2-mutant AML, the differentiation-inducing effects of IDH inhibitors (e.g., ivosidenib, enasidenib) can be potentiated by co-treatment with hypomethylating agents. Here, IDH1 is linked to acute myeloid leukemia.